Journal article
Progress and new frontiers in biomarkers for amyotrophic lateral sclerosis
- Abstract:
-
The adult-onset neurodegenerative disorder amyotrophic lateral sclerosis (ALS) is life-shortening for majority of those affected. Therapeutic trials relying on traditional endpoints such as tracheostomy-free survival, or significant reduction in the slope of decline of the revised ALS Functional Rating Score (ALSFRS-R), entail costly studies which last up to 18 months. Rapid advances in the understanding of the molecular biology of ALS are making the prospect of disease-modifying therapy i...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Authors
Funding
Bibliographic Details
- Publisher:
- Future Medicine Publisher's website
- Journal:
- Biomarkers in Medicine Journal website
- Volume:
- 12
- Issue:
- 7
- Pages:
- 693-696
- Publication date:
- 2018-06-01
- Acceptance date:
- 2018-05-18
- DOI:
- EISSN:
-
1752-0371
- ISSN:
-
1752-0363
- Pmid:
-
29856233
- Source identifiers:
-
856277
Item Description
- Language:
- English
- Keywords:
- Pubs id:
-
pubs:856277
- UUID:
-
uuid:42b53360-e76b-4237-a174-95806c2df3a4
- Local pid:
- pubs:856277
- Deposit date:
- 2018-11-06
Terms of use
- Copyright holder:
- Future Medicine Ltd
- Copyright date:
- 2018
- Notes:
- © 2018 Future Medicine Ltd. This is the accepted manuscript version of the article. The final version is available online from Future Medicine at: https://doi.org/10.2217/bmm-2018-0149
If you are the owner of this record, you can report an update to it here: Report update to this record